SCHEMBL13405609

SCHEMBL13405609

CC(C)(C)N1CCc2cc(N)ccc2C1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 1/20 0.47
HSD17B3 P37058 1/20 0.42
ESR2 Q92731 2/20 0.35
DRD1 P21728 2/20 0.35
PDK2 Q15119 1/20 0.35
GRIN2D O15399 3/20 0.35
GRIN3B O60391 3/20 0.35
GRIN1 Q05586 3/20 0.35
GRIN2A Q12879 3/20 0.35
GRIN2B Q13224 3/20 0.35
GRIN2C Q14957 3/20 0.35
GRIN3A Q8TCU5 3/20 0.35
CHRM1 P11229 2/20 0.35
ADRA1D P25100 2/20 0.35
ADRA1A P35348 2/20 0.35
ADRA1B P35368 2/20 0.35
HTR1A P08908 1/20 0.35
DRD2 P14416 1/20 0.35
HTR2A P28223 1/20 0.35
HDAC8 Q9BY41 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17797585 0.93 NR1H2 (0.54) NR1H2HSD17B3DRD1PDK2GRIN2D
SCHEMBL17797706 0.85 NR1H2 (0.44) NR1H2HSD17B3PDK2GRIN2DGRIN3B
SCHEMBL20459338 0.82 NR1H2 (0.50) NR1H2HSD17B3ESR2DRD1PDK2
SCHEMBL31370719 0.81 AKR1C3 (0.39) ESR2GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL17813373 0.81 AKR1C3 (0.39) ESR2GRIN2DGRIN3BGRIN1GRIN2A
SCHEMBL24866962 0.79 HTR2A (0.42) HSD17B3ESR2DRD1DRD2HTR2A
SCHEMBL19700137 0.79 KCNH2 (0.50) ESR2HTR1ADRD2HTR2AHDAC8
SCHEMBL13112853 0.79 HTR5A (0.36) ESR2DRD1HDAC8HDAC6KDM4E
SCHEMBL25856118 0.78 NR1H2 (0.49) NR1H2HSD17B3DRD1PDK2GRIN2D
SCHEMBL21030558 0.77 NPSR1 (0.36) ESR2PDK2HTR2AHDAC8HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160159774-A1 HETEROARYL COMPOUNDS AND USES THEREOF CELGENE CAR LLC (BM) 2016-06-09 US disclosed
WO-2016090079-A1 HETEROARYL COMPOUNDS AND USES THEREOF CELGENE AVILOMICS RESEARCH, INC. (US) 2016-06-09 WO disclosed
WO-2016090079-A1 HETEROARYL COMPOUNDS AND USES THEREOF CELGENE AVILOMICS RESEARCH, INC. (US) 2016-06-09 WO disclosed
US-7705014-B2 Inhibitors of AKT activity MERCK SHARP & DOHME CORP. (US) 2010-04-27 US disclosed
US-20090062327-A1 Inhibitors of AKT Activity MERCK SHARP & DOHME CORP. 2009-03-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090062327-A1 Inhibitors of AKT Activity PIK3CD, PIK3CA, PIK3CG NR1H2 2928/4885HSD17B3 2964/4885ESR2 1987/4885
US-20160159774-A1 HETEROARYL COMPOUNDS AND USES THEREOF ABCG2, CYP3A43, CYP3A5 NR1H2 557/4885HSD17B3 149/4885ESR2 2068/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.